Next Article in Journal
Decontamination of Ti Oxide Surfaces by Using Ultraviolet Light: Hg-Vapor vs. LED-Based Irradiation
Previous Article in Journal
Helicobacter pylori Primary and Secondary Genotypic Resistance to Clarithromycin and Levofloxacin Detection in Stools: A 4-Year Scenario in Southern Italy
Previous Article in Special Issue
Ex Vivo Murine Skin Model for B. burgdorferi Biofilm
Case Report

Efficacy of Double-Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-infections: A Report of Three Cases and Retrospective Chart Review

by 1,2,* and 2
1
HHS Babesia and Tick-borne Pathogens Subcommittee, Washington, DC 20201, USA
2
Hudson Valley Healing Arts Center, Hyde Park, NY 12538, USA
*
Author to whom correspondence should be addressed.
Antibiotics 2020, 9(11), 725; https://doi.org/10.3390/antibiotics9110725
Received: 30 August 2020 / Revised: 15 October 2020 / Accepted: 21 October 2020 / Published: 22 October 2020
(This article belongs to the Special Issue Pathogen–Host Interaction by Borrelia burgdorferi)
Three patients with multi-year histories of relapsing and remitting Lyme disease and associated co-infections despite extended antibiotic therapy were each given double-dose dapsone combination therapy (DDD CT) for a total of 7–8 weeks. At the completion of therapy, all three patients’ major Lyme symptoms remained in remission for a period of 25–30 months. A retrospective chart review of 37 additional patients undergoing DDD CT therapy (40 patients in total) was also performed, which demonstrated tick-borne symptom improvements in 98% of patients, with 45% remaining in remission for 1 year or longer. In conclusion, double-dose dapsone therapy could represent a novel and effective anti-infective strategy in chronic Lyme disease/post-treatment Lyme disease syndrome (PTLDS), especially in those individuals who have failed regular dose dapsone combination therapy (DDS CT) or standard antibiotic protocols. A randomized, blinded, placebo-controlled trial is warranted to evaluate the efficacy of DDD CT in those individuals with chronic Lyme disease/PTLDS. View Full-Text
Keywords: Lyme disease; post-treatment Lyme disease syndrome (PTLDS); dapsone combination therapy (DDS CT); double-dose dapsone combination therapy (DDD CT); babesiosis; bartonellosis; florescent in situ hybridization (FISH); persistent infection Lyme disease; post-treatment Lyme disease syndrome (PTLDS); dapsone combination therapy (DDS CT); double-dose dapsone combination therapy (DDD CT); babesiosis; bartonellosis; florescent in situ hybridization (FISH); persistent infection
Show Figures

Figure 1

MDPI and ACS Style

I. Horowitz, R.; R. Freeman, P. Efficacy of Double-Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-infections: A Report of Three Cases and Retrospective Chart Review. Antibiotics 2020, 9, 725. https://doi.org/10.3390/antibiotics9110725

AMA Style

I. Horowitz R, R. Freeman P. Efficacy of Double-Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-infections: A Report of Three Cases and Retrospective Chart Review. Antibiotics. 2020; 9(11):725. https://doi.org/10.3390/antibiotics9110725

Chicago/Turabian Style

I. Horowitz, Richard, and Phyllis R. Freeman. 2020. "Efficacy of Double-Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-infections: A Report of Three Cases and Retrospective Chart Review" Antibiotics 9, no. 11: 725. https://doi.org/10.3390/antibiotics9110725

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop